Phenotypic Drug Discovery
Chapter 7: Public–Private Partnerships to Advance Phenotypic Drug Discovery
Published:09 Dec 2020
N. Carragher, P. D. Andrews, D. Carter, T. Howe, D. Barrault, and D. Ebner, in Phenotypic Drug Discovery, ed. B. Isherwood and A. Augustin, The Royal Society of Chemistry, 2020, ch. 7, pp. 118-139.
Download citation file:
In this chapter, we discuss the rise and rationale for public–private partnerships (PPP) in phenotypic drug discovery (PDD) from both the academic and industrial perspectives. We then give a review of the three most common “precompetitive” PPP in PDD formats, namely collaborative, co-localized and industry-supported, before finally providing an outlook/conclusion, highlighting the factors we feel contribute to successful PDD partnerships, and the directions we feel these partnerships could take to improve outcomes for both partners.